Invasive vs. Conservative Management in Cancer Patients With Non-ST Elevation MI (CAN-NSTEMI)"

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital12,500 enrolled

Overview

This retrospective study investigates the impact of invasive versus conservative management strategies in cancer patients presenting with non-ST elevation myocardial infarction (non-ST MI). Patients aged 18 and older, who were treated for non-ST MI in a hospital setting and had a confirmed cancer diagnosis, are included. The primary outcome is hospital mortality, assessed using GRACE scores to evaluate mortality risk. Patients are grouped based on their received interventions-either invasive (including coronary angiography and revascularization) or pharmacological treatment. Risk factors contributing to mortality, such as cancer type, metastasis presence, comorbidities, and laboratory findings, will also be analyzed to better understand the interplay of oncologic and cardiovascular conditions in this population.

Study Type

OBSERVATIONAL

Enrollment

12,500

Conditions

Myocardial Infarction

Interventions

Observational StudyOTHER

This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age: Patients aged 18 years and older. * Diagnosis: Patients with a confirmed cancer diagnosis. * Acute Condition: Patients diagnosed with non-ST elevation myocardial infarction (non-ST MI). * Treatment: Patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-ST MI. * Consent: Patients who have provided informed consent or are part of a retrospective study where consent is waived. Exclusion Criteria: * Age: Patients younger than 18 years. * Non-cancer diagnoses: Patients without a cancer diagnosis. * ST-Elevation Myocardial Infarction: Patients with ST elevation myocardial infarction (STEMI) instead of non-ST elevation myocardial infarction (NSTEMI). * Pre-existing severe comorbidities: Patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes. * Incomplete medical records: Patients with missing data on relevant clinical variables (e.g., GRACE score, treatment received, or mortality data). * Pregnancy: Pregnant patients, as their conditions may complicate the interpretation of results. * Inability to provide informed consent: Patients unable to provide informed consent (if applicable).

Outcomes

Primary Outcomes

hospital mortality

Hospital mortality rate in cancer patients with non-ST elevation myocardial infarction, comparing invasive and conservative treatment strategies

Time frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 30 days.

Secondary Outcomes

Length of hospital stay:

Comparison of the duration of hospitalization between the invasive treatment group and the conservative treatment group.

Time frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 100 days.

Re-hospitalization rate

Rate of readmission after initial discharge, comparing the two treatment strategies.

Time frame: The time frame for assessing re-hospitalization is from the date of hospital discharge to 100 days post-discharge